Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Morbidity and Mortality of Surgical Lung Biopsy in Interstitial Lung Disease

EF 2013-14

Résumé
Interstitial lung diseases (ILDs) encompass a wide range of inflammatory lung disorders that can be related to underlying connective tissue disease, occupational or environmental exposures, drug toxicities or an unknown cause. Management and prognosis varies significantly between the different ILDs, making accurate diagnosis essential. Reaching a definitive diagnosis of ILD often requires obtaining a sample of lung tissue. Less invasive biopsy techniques, such as transbronchial biopsy, provide small tissue samples that are usually inadequate for diagnosis, necessitating a more invasive surgical lung biopsy (SLB). Previous studies suggest high peri-operative complication and mortality rates associated with SLB in patients with ILD, ranging from 3 to 16.7% at 1-2 months. However these studies are limited by very small numbers, heterogeneous populations and older surgical techniques, making interpretation of existing data and thus appropriate patient counseling difficult for physicians. Given advances in surgery towards less invasive techniques over time and the current limitations in diagnosing ILD without lung tissue, more up-to-date and robust and data on the peri-operative complications and mortality associated with SLB is needed to guide patient and physician decision making. Subsequently, the objective of our study is to determine the peri-operative risk of SLB in patients with ILD and identify factors that can predict increased patient risk. The Ontario Ministry of Health and Long Term Care is the sole insurer for health care in the province of Ontario and reimburses all emergency and hospital care, physician visits, diagnostic testing, and procedures. Consequently, information on patient characteristics and outcomes related to such care is available through provincial population health databases. This study will use Ontario Ministry of Health population databases to identify patients in Ontario who have undergone a SLB. We will be able to determine the risk of peri-operative mortality and complications, such as prolonged hospitalization, need for intensive care and re-hospitalization, in patients with ILD compared to those without ILD. We will also be able determine if certain factors (such as need for oxygen, hospitalization, sex and co-existing medical conditions) are associated with an increased surgical risk. The results of this study will allow physicians to better inform and counsel individual patients with ILD on the risks associated with SLB. Understanding the risk of SLB will also inform medical guidelines regarding the diagnosis and management of ILD.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
311672
Name
Fisher Jolene
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Morbidity and Mortality of Surgical Lung Biopsy in Interstitial Lung Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Administrative Databases; Interstitial Lung Disease; Mortality; Peri-Operative Complications; Population Databases; Pulmonary Fibrosis; Surgical Lung Biopsy
Abstract
Interstitial lung diseases (ILDs) encompass a wide range of inflammatory lung disorders that can be related to underlying connective tissue disease, occupational or environmental exposures, drug toxicities or an unknown cause. Management and prognosis varies significantly between the different ILDs, making accurate diagnosis essential. Reaching a definitive diagnosis of ILD often requires obtaining a sample of lung tissue. Less invasive biopsy techniques, such as transbronchial biopsy, provide small tissue samples that are usually inadequate for diagnosis, necessitating a more invasive surgical lung biopsy (SLB). Previous studies suggest high peri-operative complication and mortality rates associated with SLB in patients with ILD, ranging from 3 to 16.7% at 1-2 months. However these studies are limited by very small numbers, heterogeneous populations and older surgical techniques, making interpretation of existing data and thus appropriate patient counseling difficult for physicians. Given advances in surgery towards less invasive techniques over time and the current limitations in diagnosing ILD without lung tissue, more up-to-date and robust and data on the peri-operative complications and mortality associated with SLB is needed to guide patient and physician decision making. Subsequently, the objective of our study is to determine the peri-operative risk of SLB in patients with ILD and identify factors that can predict increased patient risk. The Ontario Ministry of Health and Long Term Care is the sole insurer for health care in the province of Ontario and reimburses all emergency and hospital care, physician visits, diagnostic testing, and procedures. Consequently, information on patient characteristics and outcomes related to such care is available through provincial population health databases. This study will use Ontario Ministry of Health population databases to identify patients in Ontario who have undergone a SLB. We will be able to determine the risk of peri-operative mortality and complications, such as prolonged hospitalization, need for intensive care and re-hospitalization, in patients with ILD compared to those without ILD. We will also be able determine if certain factors (such as need for oxygen, hospitalization, sex and co-existing medical conditions) are associated with an increased surgical risk. The results of this study will allow physicians to better inform and counsel individual patients with ILD on the risks associated with SLB. Understanding the risk of SLB will also inform medical guidelines regarding the diagnosis and management of ILD.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fisher, Jolene
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~